Revenue growth has fluctuated significantly, peaking at 161.9% in 2025Q1 before falling to 2.9% in 2026Q1, while operating losses reached -31.2% of revenue in the most recent quarter.
| Sales/Revenue | 41.21M | 40.93M | 32.55M | 19.24M | 15.56M | 13.86M | 7.58M | 3.84M | 2.44M | 1.56M | 1.1M | 689.67K | 913.25K |
| Revenue Growth % | 6.68% | 25.73% | 69.17% | 23.7% | 12.26% | 82.72% | 97.6% | 57.02% | 56.79% | 41.29% | 59.97% | -24.48% | - |
| Cost of Goods Sold | 14.03M | 14.04M | 9.37M | 6.06M | 5.3M | 3.54M | 2.6M | 917.62K | 728.28K | 505.28K | 282.16K | 244.41K | 211.58K |
| COGS % of Revenue | - | 34.3% | 28.77% | 31.49% | 34.09% | 25.58% | 34.29% | 23.91% | 29.8% | 32.41% | 25.58% | 35.44% | 23.17% |
| Gross Profit | 27.18M | 26.89M | 23.19M | 13.18M | 10.25M | 10.31M | 4.98M | 2.92M | 1.72M | 1.05M | 821.11K | 445.26K | 701.67K |
| Gross Margin % | 65.96% | 65.7% | 71.23% | 68.51% | 65.91% | 74.42% | 65.71% | 76.09% | 70.2% | 67.59% | 74.42% | 64.56% | 76.83% |
| Gross Profit Growth % | - | 15.97% | 75.88% | 28.57% | -0.57% | 106.95% | 70.64% | 70.19% | 62.86% | 28.31% | 84.41% | -36.54% | - |
| Operating Expenses | 41.22M | 41.29M | 29.39M | 21.41M | 20.93M | 20.58M | 15.49M | 13.72M | 12.24M | 7.6M | 4.1M | 3.98M | 3.44M |
| OpEx % of Revenue | - | 100.88% | 90.29% | 111.29% | 134.52% | 148.53% | 204.21% | 357.38% | 500.97% | 487.64% | 371.27% | 576.91% | 377% |
| Selling, General & Admin | 34.44M | 34.35M | 24.62M | 18.78M | 18.44M | 18.02M | 13.82M | 11.55M | 10.41M | 5.85M | 2.98M | 3.22M | 2.86M |
| SG&A % of Revenue | - | 83.92% | 75.63% | 97.59% | 118.56% | 130.07% | 182.19% | 301.08% | 425.74% | 375.27% | 269.67% | 467.17% | 313.45% |
| Research & Development | 6.78M | 6.94M | 4.77M | 2.64M | 2.48M | 2.56M | 1.67M | 2.16M | 1.84M | 1.75M | 1.12M | 869.13K | 675.21K |
| R&D % of Revenue | - | 16.97% | 14.66% | 13.7% | 15.96% | 18.46% | 22.01% | 56.3% | 75.23% | 112.37% | 101.6% | 126.02% | 73.93% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -1.1K | -16.95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -14.04M | -14.4M | -6.21M | -8.23M | -10.67M | -10.27M | -10.5M | -10.8M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Operating Margin % | -34.07% | -35.19% | -19.07% | -42.78% | -68.61% | -74.1% | -138.5% | -281.29% | -430.77% | -420.06% | -296.84% | -512.35% | -300.17% |
| Operating Income Growth % | - | -132.04% | 24.6% | 22.87% | -3.94% | 2.23% | 2.71% | -2.53% | -60.79% | -99.94% | 7.32% | -28.9% | - |
| EBITDA | -12.72M | -12.64M | -5.43M | -7.71M | -10.13M | -9.93M | -10.39M | -10.7M | -10.46M | -6.54M | -3.27M | -3.53M | -2.74M |
| EBITDA Margin % | -30.87% | -30.88% | -16.68% | -40.09% | -65.12% | -71.68% | -137.06% | -278.81% | -427.92% | -419.32% | -296.14% | -511.58% | -299.5% |
| EBITDA Growth % | -170.54% | -132.74% | 29.61% | 23.85% | -1.99% | 4.44% | 2.86% | -2.31% | -60% | -100.07% | 7.4% | -28.99% | - |
| D&A (Non-Cash Add-back) | 1.32M | 1.76M | 776.97K | 517.68K | 542.63K | 335.96K | 108.67K | 95.12K | 69.68K | 11.41K | 7.73K | 5.31K | 6.16K |
| EBIT | -14.04M | -14.4M | -5.82M | -8.23M | -10.67M | -10.27M | -11.09M | -10.8M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Net Interest Income | -1.15M | -450.83K | 388.59K | 410.27K | 88.73K | 1.61K | -474.71K | -113.63K | 175.41K | -5.53M | -342.02K | 0 | 0 |
| Interest Income | 106.55K | 476.97K | 388.59K | 410.27K | 88.73K | 1.61K | 0 | - | 0 | 0 | 0 | 196.06K | 178.86K |
| Interest Expense | 1.25M | 927.8K | 0 | 0 | 0 | 0 | 474.71K | 113.63K | 358.92K | 358.92K | 342.02K | 0 | 0 |
| Other Income/Expense | -525.13K | -667.5K | 388.59K | 239.99K | 21.12K | -15.34K | -1.06M | 81.99K | 211.68K | -5.55M | -342.02K | -196.06K | -178.86K |
| Pretax Income | -14.56M | -15.07M | -5.82M | -7.99M | -10.65M | -10.28M | -11.56M | -10.71M | -10.32M | -12.1M | -3.62M | -3.73M | -2.92M |
| Pretax Margin % | -35.34% | -36.82% | -17.87% | -41.53% | -68.47% | -74.21% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -540.77% | -319.76% |
| Income Tax | 554.45K | 504.53K | 365.62K | 156K | 69.94K | 88.93K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -3.81% | -3.35% | -6.28% | -1.95% | -0.66% | -0.86% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -15.12M | -15.57M | -6.18M | -8.15M | -10.72M | -10.37M | -11.56M | -10.71M | -10.32M | -12.1M | -3.62M | -4.48M | -3.53M |
| Net Margin % | -36.69% | -38.05% | -19% | -42.34% | -68.92% | -74.86% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -649.9% | -386.29% |
| Net Income Growth % | -160.07% | -151.85% | 24.1% | 24% | -3.36% | 10.3% | -7.94% | -3.84% | 14.72% | -234.46% | 19.3% | -27.05% | - |
| Net Income (Continuing) | -15.12M | -15.57M | -6.18M | -8.15M | -10.72M | -10.37M | -11.56M | -10.71M | -10.32M | -12.1M | -3.62M | -3.73M | -2.92M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.36 | -0.37 | -0.16 | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.15 | -84.05 | -0.56 | -134.56 | -106.03 |
| EPS Growth % | -147.19% | -131.25% | 42.86% | 81.58% | 14.61% | 50.83% | 81.15% | 23.66% | 70.08% | -14908.93% | 99.58% | -26.91% | - |
| EPS (Basic) | - | -0.37 | -0.16 | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.18 | -84.05 | -0.56 | -134.56 | -106.03 |
| Diluted Shares Outstanding | 42.27M | 41.86M | 37.76M | 29.5M | 7.05M | 5.83M | 3.33M | 553.79K | 410.15K | 143.93K | 6.41M | 33.31K | 33.27K |
| Basic Shares Outstanding | 42.27M | 41.86M | 37.76M | 29.1M | 7.05M | 5.83M | 3.33M | 553.79K | 409.75K | 143.93K | 6.41M | 33.31K | 33.27K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - |
Liquidity and cash depletion
According to quarterly financial data, Myomo's revenue growth has fluctuated wildly, peaking at 161.9% in 2025Q1 before decelerating to 2.9% by 2026Q1, suggesting that the company's reliance on lumpy insurance authorizations creates an unpredictable top-line trajectory that complicates long-term forecasting for institutional investors.
The extreme variance in year-over-year growth rates highlights the inherent friction in the company's reimbursement-dependent business model. Investors should interpret these swings as evidence that revenue recognition is tied more to administrative success in securing insurance approvals than to consistent market demand or organic sales velocity.
As reported in recent income statements, Myomo maintains a relatively robust gross margin profile, averaging approximately 65-70% over the last ten quarters, which indicates that the underlying product value remains high despite the significant labor costs associated with custom-fitting each individual patient device.
While the gross margin appears healthy for a medical device firm, it remains structurally constrained by the high-touch nature of the patient advocacy and fitting process. This suggests that unless the company can achieve significant economies of scale in its manufacturing or fitting operations, gross margin expansion will likely remain capped.
Based on the provided income statement figures, Myomo has failed to demonstrate positive operating leverage, as SG&A expenses consistently outpace gross profit, resulting in persistent operating losses that reached -31.2% of revenue in 2026Q1, indicating that the company's overhead remains disproportionately high relative to its scale.
The inability to scale operating income faster than gross profit suggests that the company's current infrastructure for patient acquisition and reimbursement is not yet optimized for profitability. This implies that management must either significantly increase unit volume or drastically reduce the cost of patient acquisition to reach a sustainable operating margin.
Financial statements reveal that Myomo's TTM net loss of approximately $15.5M stands in stark contrast to its $14.1M cash reserve, suggesting that the company faces a critical liquidity inflection point that may necessitate further dilutive equity financing to sustain its current operational burn rate.
Short-sellers would likely focus on the mismatch between the company's cash runway and its persistent inability to generate positive net income. This warrants further investigation into whether the current sales pipeline can convert to cash quickly enough to avoid a balance sheet crisis in the coming fiscal year.
Quick answers to the most common questions about buying MYO stock.
For fiscal year 2025, Myomo, Inc. (MYO) reported total revenue of $40.9M. This represents a 4381.6% increase compared to $0.9M in 2014.
Myomo, Inc. (MYO) reported a net loss of $15.6M for the fiscal year ending 2025.
Myomo, Inc. (MYO) reported an operating income of $-14.4M, resulting in an operating profit margin of -35.2%. This margin reflects the operational efficiency of the business before interest and taxes.
Myomo, Inc. (MYO) generated $26.9M in gross profit for the year, representing a gross profit margin of 65.7%. This demonstrates the company's core pricing power and production efficiency.